Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26199
Title: Novel Approach to Risk Stratification in Left Ventricular Non-Compaction Using A Combined Cardiac Imaging and Plasma Biomarker Approach.
Austin Authors: Ramchand, Jay ;Podugu, Pooja;Obuchowski, Nancy;Harb, Serge C;Chetrit, Michael;Milinovich, Alex;Griffin, Brian;Burrell, Louise M ;Wilson Tang, W H;Kwon, Deborah H;Flamm, Scott D
Affiliation: Medicine (University of Melbourne)
Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH
Imaging Institute, Cleveland Clinic, Cleveland, OH
Issue Date: 9-Apr-2021
metadata.dc.date: 2021-04-09
Publication information: Journal of the American Heart Association 2021: e019209
Abstract: Background Left ventricular non-compaction remains a poorly described entity, which has led to challenges of overdiagnosis. We aimed to evaluate if the presence of a thin compacted myocardial layer portends poorer outcomes in individuals meeting cardiac magnetic resonance criteria for left ventricular non-compaction . Methods and Results This was an observational, retrospective cohort study involving individuals selected from the Cleveland Clinic Foundation cardiac magnetic resonance database (N=26 531). Between 2000 and 2018, 328 individuals ≥12 years, with left ventricular non-compaction or excessive trabeculations based on the cardiac magnetic resonance Petersen criteria were included. The cohort comprised 42% women, mean age 43 years. We assessed the predictive ability of myocardial thinning for the primary composite end point of major adverse cardiac events (composite of all-cause mortality, heart failure hospitalization, left ventricular assist device implantation/heart transplant, ventricular tachycardia, or ischemic stroke). At mean follow-up of 3.1 years, major adverse cardiac events occurred in 102 (31%) patients. After adjusting for comorbidities, the risk of major adverse cardiac events was nearly doubled in the presence of significant compacted myocardial thinning (hazard ratio [HR], 1.88 [95% CI, 1.18‒3.00]; P=0.016), tripled in the presence of elevated plasma B-type natriuretic peptide (HR, 3.29 [95% CI, 1.52‒7.11]; P=0.006), and increased by 5% for every 10-unit increase in left ventricular end-systolic volume (HR, 1.01 [95% CI, 1.00‒1.01]; P=0.041). Conclusions The risk of adverse clinical events is increased in the presence of significant compacted myocardial thinning, an elevated B-type natriuretic peptide or increased left ventricular dimensions. The combination of these markers may enhance risk assessment to minimize left ventricular non-compaction overdiagnosis whilst facilitating appropriate diagnoses in those with true disease.
URI: https://ahro.austin.org.au/austinjspui/handle/1/26199
DOI: 10.1161/JAHA.120.019209
PubMed URL: 33834849
Type: Journal Article
Subjects: biomarkers
cardiac magnetic resonance
cardiomyopathy
echocardiography
non‐compaction
Appears in Collections:Journal articles

Show full item record

Page view(s)

16
checked on May 8, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.